This concern provided a rationale for the phase 3 CREATE-X trial (UMIN000000843), which tested whether adjuvant capecitabine improves OS for patients with HER2-negative breast cancer who failed to attain pCR with NAC54. The gene discussed is ERBB2; the disease is breast carcinoma.